WO2024240173 - AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES

National phase entry:
Publication Number WO/2024/240173
Publication Date 28.11.2024
International Application No. PCT/CN2024/094651
International Filing Date 22.05.2024
Title **
[English] AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES
[French] CONJUGUÉ ANTICORPS-MÉDICAMENT AYANT AU MOINS DEUX COMPOSÉS À PETITES MOLÉCULES FONCTIONNELS POUR LE TRAITEMENT AMÉLIORÉ DE MALADIES RÉFRACTAIRES
Applicants **
HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD
ZHAO, Robert Yongxin
HANGZHOU DAC BIOTECH CO., LTD
Inventors
YANG, Qingliang
HUANG, Yuanyuan
YE, Hangbo
ZHANG, Lingli
GUO, Huihui
JIA, Junxiang
BAI, Lu
WANG, Juan
LI, Wenjun
Priority Data
PCT/CN2023/096066   24.05.2023   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting14650
EPO Filing, Examination, Granting44941
Japan Filing, Examination, Granting2424
South Korea Filing, Examination, Granting2542
USA Filing, Examination, Granting13540
MasterCard Visa
Total: 78,097

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] An antibody-drug conjugate containing a side chain of a functional small molecule for enhancement of targeted treatment of cancers and refractory diseases is provided. The preparation of such conjugate, pharmaceutical compositions, and methods in treatment of refractory diseases are also provided.[French] L'invention concerne un conjugué anticorps-médicament contenant une chaîne latérale d'une petite molécule fonctionnelle pour l'amélioration du traitement ciblé de cancers et de maladies réfractaires. L'invention concerne également la préparation d'un tel conjugué, des compositions pharmaceutiques et des méthodes de traitement de maladies réfractaires.

Rejoining the server...